Schoenberg Mark's Form 4 filing
UroGen Pharma Ltd. (URGN) · filed Feb 2, 2023
- Accession no.
- 0001437749-23-002336
- Filed
- Feb 2, 2023
- Trade date
- Jan 31, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 5 derivative transactions. Open-market sales total $19.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schoenberg MarkCIK 0001763581 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 31, 2023 | Ordinary Shares | MOption exerciseAcquired | +500 | – | – | 147,127 | Direct | |
| Jan 31, 2023 | Ordinary Shares | SSaleDisposed | −248 | $10.12 | −$2,509.76 | 146,879 | Direct | |
| Jan 31, 2023 | Ordinary Shares | MOption exerciseAcquired | +2,000 | – | – | 148,879 | Direct | |
| Jan 31, 2023 | Ordinary Shares | SSaleDisposed | −991 | $10.12 | −$10,028.92 | 147,888 | Direct | |
| Jan 31, 2023 | Ordinary Shares | MOption exerciseAcquired | +1,333 | – | – | 149,221 | Direct | |
| Jan 31, 2023 | Ordinary Shares | SSaleDisposed | −661 | $10.12 | −$6,689.32 | 148,560 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 31, 2023 | Ordinary Shares | MOption exerciseDisposed | −500 | $0.00 | $0 | 0 | Direct | |
| Jan 31, 2023 | Ordinary Shares | MOption exerciseDisposed | −2,000 | $0.00 | $0 | 2,000 | Direct | |
| Jan 31, 2023 | Ordinary Shares | MOption exerciseDisposed | −1,333 | $0.00 | $0 | 2,667 | Direct | |
| Jan 31, 2023 | Ordinary Shares | AGrant or awardAcquired | +10,000 | $0.00 | $0 | 10,000 | Direct | |
| Jan 31, 2023 | Ordinary Shares | AGrant or awardAcquired | +30,000 | $0.00 | $0 | 30,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.